

Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from Phase 1 and Phase 2a studies

Katie Zomorodi, Grace Wang, Steven J Knox, Julie Ma, Luisa M Stamm

Assembly Biosciences, Inc., South San Francisco, CA, USA

Background

- Chronic hepatitis B virus infection (cHBV) is a significant global health problem
 - Worldwide, an estimated 296 million people have cHBV infection, resulting in approximately 887,000 deaths each year, mostly due to cirrhosis and hepatocellular carcinoma¹⁻⁴
- For most patients, nucleos(t)ide reverse transcriptase inhibitors (NrtIs) are effective in reducing HBV DNA and are well tolerated, but treatment duration is indefinite⁵
- Novel combination approaches incorporating agents with complementary mechanisms of action will likely be required to further suppress viral replication and establish finite-duration regimens
- Agents included in these combination regimens require favorable drug-drug interaction (DDI) profiles to allow concomitant administration to treat comorbid conditions in patients with cHBV^{6,7}
 - Vebicorvir (VBR), a first-generation HBV core inhibitor, administered with NrtIs over 24 weeks, has demonstrated greater HBV DNA and pregenomic RNA suppression than NrtI monotherapy in patients with cHBV infection in Phase 2 studies⁸⁻¹⁰
 - VBR is orally administered as 300 mg once daily without regard to food and has a favorable clinical safety profile in over 100 patients treated for up to 1.5 years in a Phase 2 study¹¹
- VBR is not a potent inhibitor of cytochrome P450s (CYPs) or drug transporters in vitro
 - VBR concentrations that achieve 50% inhibition (IC₅₀) were >25 μM for tested CYPs
 - VBR IC₅₀s were >10 μM for tested transporters


Objective of this analysis

- To evaluate VBR's DDI potential based on clinical data:
 - A Phase 1 study in which VBR was administered in combination with several CYP index substrates (CYPs 2C9, 2C19, 2D6, 2C8, 3A4, and 2B6) to healthy participants
 - Two Phase 2a studies in which VBR was administered in combination with NrtIs to virologically-suppressed and treatment-naïve patients with cHBV

Methods

- Data from 3 VBR clinical studies are included:
 - Study 103 was a 3-part, Phase 1 DDI study in healthy participants (Figure 1, left panel)
 - Part 1 investigated the potential impact of VBR at steady state on the oral pharmacokinetics (PK) of the index substrates tolbutamide (2C9), omeprazole (2C19), dextromethorphan (2D6), and repaglinide (2C8)
 - Part 2 determined the effect of VBR at steady state on the PK of midazolam (3A4)
 - Part 3 evaluated the effect of VBR at steady state on the PK of bupropion (2B6)
 - Intensive PK samples were collected in all parts, and PK analysis was conducted by noncompartmental methods
- Studies 201 (NCT03577171; N=73) and 202 (NCT03576066; N=25) were Phase 2a, double-blind, placebo-controlled trials evaluating VBR+NrtIs in patients with cHBV (Figure 1, right panel)
 - Sparse PK samples were collected
 - Trough (predose) on Day 1 and at Weeks 2, 4, 12, and 24
 - 4 hours postdose on Day 1 and Weeks 2 and 4
 - Plasma concentrations of all analytes were determined using validated tandem mass spectrometry bioanalytical methods

Figure 1. Design of studies




Results

Table 1. Study 103: Demographics and Baseline characteristics

	Part 1 (n=20)	Part 2 (n=18)	Part 3 (n=20)
Age, years; mean (min, max)	34.3 (24, 48)	31.8 (21, 44)	35.6 (20, 47)
Sex, female; n (%)	11 (55.0)	6 (33.3)	4 (20.0)
Race; n (%)			
American Indian or Alaska Native	1 (5.0)	0	0
Black or African American	8 (40.0)	8 (44.4)	10 (50.0)
White	11 (55.0)	10 (55.6)	10 (50.0)
BMI, kg/m ² ; mean (SD)	27.16 (3.05)	25.63 (3.89)	26.11 (2.88)

Figure 2. Study 103: DDI of VBR on CYP index substrates



GLS means ratios and 90% CIs for combination/alone comparison against each PK parameter were derived from a mixed effect model evaluation. The log-transformed PK parameters were analyzed using a mixed effect model, with day as a fixed effect and participant as a random effect. AUC_{0-∞}, area under the curve from time 0 to time of last measurable concentration; CI, confidence interval; C_{max}, maximum observed plasma concentration; CYP, cytochrome P450s; DDI, drug-drug interaction; GLS, geometric least square; PK, pharmacokinetic; VBR, vebicorvir.


- Part 1 (Figure 2, left panel):
 - Maximum plasma concentrations (C_{max}) and area under the curve (AUC) parameter ratios (combination/alone) for omeprazole (2C19), dextromethorphan (2D6), and repaglinide (2C8) were within acceptable clinical ranges, demonstrating no DDI potential
 - Tolbutamide AUC was increased by approximately 30% with VBR coadministration, suggesting that VBR is a weak inhibitor of CYP2C9
- Part 2 (Figure 2, middle panel):
 - Midazolam AUC was reduced by 33% following 6 days of VBR administration (Day 7), with no further reduction after another 8 days of VBR administration (Day 15). There was no concomitant change in 1-hydroxymidazolam AUC on either Day 7 or Day 15, suggesting that VBR is not an inhibitor or inducer of CYP3A4
- Part 3 (Figure 2, right panel):
 - Coadministration of VBR did not have an effect on the C_{max} or AUC of bupropion, suggesting that VBR is not an inhibitor or inducer of CYP2B6

Table 2. Study 201 and 202: Demographics and Baseline characteristics

	Study 201 (N=73)	Study 202 (N=25)
Age, years; median (min, max)	45.0 (20, 66)	32.0 (20, 66)
Aged >65 years; n (%)	1 (1)	1 (4)
Sex, female; n (%)	26 (36)	17 (68)
Race, Asian; n (%)	61 (84)	24 (96)
BMI, kg/m ² ; mean (SD)	24.0 (3.44)	23.3 (3.59)
NrtI at randomization; n (%)		
ETV ^a	10 (14)	NA ^b
TAF	22 (30)	NA ^b
TDF ^a	42 (58)	NA ^b

^aOne patient was taking both ETV and TDF. ^bAll Study 202 patients were treatment-naïve when entering the study, and all received ETV. BMI, body mass index; ETV, entecavir; max, maximum; min, minimum; NA, not applicable; NrtI, nucleos(t)ide reverse transcriptase inhibitor; SD, standard deviation; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.


Figure 3. Study 201: Plasma VBR trough concentrations following combination therapy in patients with cHBV (by NrtI therapy)



Study 201 (Figure 3)

- After Day 1, mean trough plasma concentration values of VBR ranged from 1280–1600 ng/mL, 1310–1410 ng/mL, and 1310–1410 ng/mL for pooled VBR+entecavir (ETV), VBR+tenofovir alafenamide (TAF), and VBR+tenofovir disoproxil fumarate (TDF), respectively, and were in agreement with VBR monotherapy. The variability generally remained consistent across all combination treatments


Figure 4. Study 201: Plasma NrtI trough concentrations following combination therapy in patients with cHBV (by NrtI therapy)



Study 201 (Figure 4)

- ETV mean trough plasma concentration values were generally similar between both arms of the study, ranging from 0.554–1.10 ng/mL with VBR and 0.346–1.78 ng/mL with placebo, and were in agreement with published data
- In the TAF group, tenofovir mean trough plasma concentrations ranged from 13.1–21.3 ng/mL when coadministered with VBR and from 11.7–14.1 ng/mL when coadministered with placebo, and were in agreement with published data
- In the TDF group, tenofovir mean trough plasma concentrations were generally similar between both arms of the study, ranging from 72.4–86.8 ng/mL with VBR and 76.2–89.1 ng/mL with placebo, and were in agreement with published data

Figure 5. Study 202: Plasma trough concentrations following combination therapy in patients with cHBV



Study 202 (Figure 5)

- Mean trough plasma concentrations of VBR remained consistent, ranging from 1270–1480 ng/mL with similar variability across visits, and were in agreement with VBR monotherapy
- ETV mean trough plasma concentration values were generally similar between both arms of the study, ranging from 0.378–0.432 ng/mL with VBR and 0.408–0.666 ng/mL with placebo, and were in agreement with published data

Conclusions

- Based on the Phase 1 study, VBR is a weak inhibitor of CYP2C9, is not an inhibitor of CYP2C19, 2D6, or 2C8, and is not an inhibitor/inducer of CYP3A4 or 2B6
- Results from the Phase 2a studies suggest no clinically significant DDI between VBR and NrtIs
- VBR shows a favorable profile, with limited potential for DDI when used in combination with NrtIs and other medications

References

1) European Association for the Study of the Liver. *J Hepatol*. 2017; 67:370–98. 2) World Health Organization. Global Hepatitis Report. 2017. 3) World Health Organization. Key Facts. 2021. <https://www.who.int/news-room/fact-sheets/detail/hepatitis>. Accessed March 10, 2022. 4) El-Serag HB, et al. *Gastroenterology*. 2012; 142:1264–73. 5) Seto WK, et al. *Lancet*. 2018;10161:2313–24. 6) Wong GLH, et al. *Hepatology*. 2020;244:44–55. 7) Liu A, et al. *Clin Transl Gastroenterol*. 2018;3:141. 8) Fung S, et al. Poster presentation at EASL, Aug 27–29, 2020. 9) Yuen MF, et al. Poster presentation at EASL, Aug 27–29, 2020. 10) Ma X, et al. Oral presentation at EASL, April 10–14, 2019. 11) Jacobson I, et al. *Hepatology*. 2020;72(suppl S1):820.

Acknowledgments

We express our gratitude to all the healthy participants and patients, investigators, and site staff who contributed to the study. Writing and editorial support were provided by Gregory Suess, PhD, of AlphaScientia, LLC, and funded by Assembly Biosciences. This study was sponsored by Assembly Biosciences.